Abstract
Heat shock protein (Hsp90) inhibitors are an increasingly interesting and important class of compounds where the first in class, natural product derived inhibitors such as 17-allylaminogeldanamycin (17-AAG), are entering late stage clinical development. Recently the emergence of synthetic, small molecule inhibitors has been described and both NVPAUY922 and BIIB021 have entered clinical development. The medicinal chemistry of these and other published small molecule Hsp90 inhibitors is described in this review.
Keywords: Hsp90, anti-cancer, structure-based design
Current Topics in Medicinal Chemistry
Title: Medicinal Chemistry of Hsp90 Inhibitors
Volume: 8 Issue: 10
Author(s): Martin J. Drysdale and Paul A. Brough
Affiliation:
Keywords: Hsp90, anti-cancer, structure-based design
Abstract: Heat shock protein (Hsp90) inhibitors are an increasingly interesting and important class of compounds where the first in class, natural product derived inhibitors such as 17-allylaminogeldanamycin (17-AAG), are entering late stage clinical development. Recently the emergence of synthetic, small molecule inhibitors has been described and both NVPAUY922 and BIIB021 have entered clinical development. The medicinal chemistry of these and other published small molecule Hsp90 inhibitors is described in this review.
Export Options
About this article
Cite this article as:
Drysdale J. Martin and Brough A. Paul, Medicinal Chemistry of Hsp90 Inhibitors, Current Topics in Medicinal Chemistry 2008; 8 (10) . https://dx.doi.org/10.2174/156802608784911644
DOI https://dx.doi.org/10.2174/156802608784911644 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
RNA Splicing: Basic Aspects Underlie Antitumor Targeting
Recent Patents on Anti-Cancer Drug Discovery Chagas Disease Chemotherapy: What Do We Know So Far?
Current Pharmaceutical Design Emerging Antimicrobial Applications of Nitric Oxide (NO) and NO-Releasing Materials
Anti-Infective Agents in Medicinal Chemistry Review on Documented Medicinal Plants used for the Treatment of Cancer
Current Traditional Medicine Patent Selections
Recent Patents on Anti-Infective Drug Discovery Lipid-based Nanoplatforms in Cancer Therapy: Recent Advances and Applications
Current Cancer Drug Targets De Novo DNMTs and DNA Methylation: Novel Insights into Disease Pathogenesis and Therapy from Epigenomics
Current Pharmaceutical Design Co-formulation of P-glycoprotein Substrate and Inhibitor in Nanocarriers: An Emerging Strategy for Cancer Chemotherapy
Current Cancer Drug Targets Fibroblast Growth Factors, Fibroblast Growth Factor Receptors, Diseases, and Drugs
Recent Patents on Cardiovascular Drug Discovery Antidepressant-Like Components of Hypericum perforatum Extracts: An Overview of Their Pharmacokinetics and Metabolism
Current Drug Metabolism Applications of Mesoporous Materials as Excipients for Innovative Drug Delivery and Formulation
Current Pharmaceutical Design Novel 4- Aryl-2(1H)-phthalazinone Derivatives as Cyclooxygenase-2 Inhibitors: Synthesis, Molecular Modeling Study and Evaluation as Promising Anti-inflammatory Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Role of Amino Acids in the Modulation of Cardiac Metabolism During Ischemia and Heart Failure
Current Pharmaceutical Design Editorial: [Hot Topics: A New Horizon of Herbal Medicines in Anorexia-Cachexia Syndrome]
Current Pharmaceutical Design Recent Patents on Anti-Cancer Potential of Helenalin
Recent Patents on Anti-Cancer Drug Discovery Dextran-based Nanocarriers for Delivery of Bioactives
Current Pharmaceutical Design Aspirin as a Chemoprevention Agent for Colorectal Cancer
Current Drug Metabolism Epstein-Barr Virus-associated Gastric Cancer and Potential Mechanisms of Oncogenesis
Current Cancer Drug Targets Nitric Oxide: News from Stem Cells to Platelets
Current Medicinal Chemistry Recent Developments in the Pharmacological Properties of 4'-Geranyloxyferulic Acid, a Colon Cancer Chemopreventive Agent of Natural Origin
Current Drug Targets